Quick Answer
IRADIMED CORP reported Cash and Equivalents of $51.16 million for fiscal year 2025.
IRADIMED CORP Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $51.16M | -2.1% |
| 2024 | $52.23M | +5.0% |
| 2023 | $49.76M | -14.1% |
| 2022 | $57.96M | -6.5% |
| 2021 | $62.00M | +23.8% |
| 2020 | $50.07M | +15.1% |
| 2019 | $43.48M | +55.1% |
| 2018 | $28.03M | +53.9% |
| 2017 | $18.21M | +2.8% |
| 2016 | $17.71M | -8.5% |
| 2015 | $19.37M | +104.9% |
| 2014 | $9.45M | +284.1% |
| 2013 | $2.46M | +45.0% |
| 2012 | $1.70M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.53M | +9.3% | +6.7% |
| June 30, 2025 | $53.00M | +9.2% | +5.3% |
| March 31, 2025 | $50.33M | +11.5% | -3.6% |
| December 31, 2024 | $52.23M | +5.0% | +1.0% |
| September 30, 2024 | $51.72M | +10.6% | +6.6% |
| June 30, 2024 | $48.54M | +5.9% | +7.6% |
| March 31, 2024 | $45.13M | +5.5% | -9.3% |
| December 31, 2023 | $49.76M | -14.1% | +6.5% |
- IRADIMED CORP showed a decrease of -2.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, IRADIMED CORP’s cash and equivalents has grown by 2914.1% (from $1.70 million to $51.16 million).
- The most recent figure is from IRADIMED CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: